ADPT Adaptive Biotechnologies Corporation

XNAS 30.26 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ADPT $30.26 —
Key stats
$30.26
52-Week Range
$12.00 – $30.79
YTD
+90.19%
IV Rank (30D)
72.21
Straddle Price
$7.52
P/C Vol Ratio
0.77
Market Cap
$4.5B
Open
$28.53
Day Range
$28.23 – $30.79
Volume
2,831,590
Prev Close
$27.98
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY1.50
Cost of Equity (CAPM)13.16% (VRP-adj)
WACC12.69%
Volatility Risk Premium+45.6pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon5 years explicit + fade
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-44.7%
Book / Price3.4%
Gross Margin (TTM)75.6%
FCF Margin (TTM)-7.8%
Debt / Equity2.22
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$26.42 (Market Anchor value)
SMA 20 / Bollinger Mid$25.96
Bollinger Width / SMA2020.2% (drives anchor stability)
Net Debt$0.2B
Market Cap$4B
Peers used for multiples: CDNA, CRSP, GH, LLY, MRNA, NTRA, TWST, VRTX
60-Day Conviction
55%
20-Day Fair Value
≈ by Dec 8, 2026
$29.83
α -1.4% rank 25%
conviction
81%
40-Day Fair Value
≈ by Jan 6, 2027
$29.90
α -1.2% rank 25%
conviction
42%
60-Day Fair Value
≈ by Feb 4, 2027
$29.61
α -2.2% rank 25%
conviction
55%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 34.6× · 3 peers
Peer EV/EBITDA n/a 0% median 29.7× · 3 peers
Peer P/B $13.44 22% median 14.3× · 7 peers
Peer P/S $34.61 22% median 18.0× · 8 peers
Market Anchor (SMA50) $26.42 56% stability 49% (BB-width)
Options Expected (B-L 30d) $28.05 0% 8 strikes · skew -0.01
As of 2026-11-09 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$4.5B
Employees
624
List Date
2019-06-27
CIK
0001478320
Last Earnings
Nov 4 before open · +3.5% vs ±19.1% expected
Headquarters
Seattle, WA
Homepage
https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company ha…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-0.64%-39.65%18.85%-23.06%25.20%16.28%-0.50%
Feb0.68%-18.93%-8.85%9.89%7.27%-12.89%-3.80%
Mar-30.45%-2.60%8.61%-20.35%-8.27%-13.90%-11.16%
Apr2.04%-43.99%-18.03%-15.76%-2.13%-2.29%-13.36%
May-0.55%-9.70%-5.31%23.66%29.35%6.17%7.27%
Jun11.55%10.82%-4.82%9.37%21.99%40.84%14.96%
Jul-8.05%8.79%26.35%26.39%-8.49%0.80%7.63%
Aug-1.28%-2.62%-17.94%5.62%27.59%7.83%3.20%
Sep-10.20%-20.27%-19.97%14.03%16.51%18.73%-0.19%
Oct0.30%7.31%-14.45%-3.59%19.23%-2.67%1.02%
Nov-26.17%4.40%-1.35%11.86%13.38%20.75%*3.81%
Dec11.39%-11.68%4.26%-8.19%-13.80%---3.60%
Total-47.04%-77.68%-36.54%15.64%201.59%93.26%24.87%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $26.19
SMA 50: $26.52
SMA 200: $19.87
Current: $30.26
EMA 12: $27.19
EMA 26: $26.74
MACD: 0.4568 | Signal: 0.3541
BULLISH
ADX (14): 15.73
RANGE
+DI: 29.64
−DI: 16.28

Momentum Oscillators

RSI (14): 64.81
NEUTRAL
Stoch %K: 76.52
Stoch %D: 63.62
Williams %R: -7.54

Volume & Volatility

BB Upper: $29.41
BB Lower: $22.98
OVERBOUGHT
OBV: 68,310,658
Vol SMA 20: 2,183,348
Vol ROC: 142.80%
ATR: $1.73
True Range: $2.80
HV 20: 61.9%
HV 30: 65.9%
HV 60: 54.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Written before ADPT’s Nov 4 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BEARISH (Confidence Level: 7/10)

Key Drivers:

  • Negative news sentiment
  • Bearish momentum indicators
  • High volatility

Primary Risks:

  • Oversold RSI
  • Low institutional interest

Investment Thesis: ADPT is trading in a downtrend, driven by negative news sentiment and bearish momentum signals. The stock has high volatility, making it a higher-risk investment.

Recent News Sentiment Impact: The recent news headlines are overwhelmingly negative, with several executives selling shares under 10b5-1 plans and tax-driven share sales. This negative news sentiment is likely contributing to the stock's downtrend.

Technical Analysis

Trend Direction:

  • Short-term: BEARISH
  • Medium-term: BEARISH
  • Long-term: NEUTRAL

Support/Resistance Levels:

  • SMA 20: $15.34 (resistance)
  • SMA 50: $16.51 (resistance)
  • Upper Bollinger Band: $17.43 (resistance)

Momentum Signals:

  • RSI (14): 32.73 (oversold)
  • MACD: -0.81 / Signal: -0.26 / Histogram: -0.55 (bearish)
  • Stochastic %K: 15.73
  • Stochastic %D: 15.36

Volume Analysis:

  • Volume SMA 20: 1682602.68
  • On-Balance Volume (OBV): 28951816.77
  • Volume Rate of Change: N/A%

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines are mostly negative, with several executives selling shares under 10b5-1 plans and tax-driven share sales.

Sentiment Assessment: The overall sentiment is NEGATIVE, driven by the recent news headlines.

Catalyst Identification: There are no near-term catalysts that could significantly impact the stock's price.

Market Narrative: The market narrative is bearish, with negative news sentiment driving the downtrend.

Risk & Volatility Assessment

Risk Metrics:

  • Beta: 1.39 (high risk)
  • Alpha: 0.60
  • Correlation: 0.36
  • Stock Volatility: 0.73

Options Market Signals: The options market is pricing a $3.27 move by expiration, indicating high volatility.

Downside Protection: The stock has strong technical support at the SMA 20 and SMA 50 levels.

Market Context & Positioning

Sector Performance: ADPT is underperforming its sector, with a negative correlation.

Institutional Activity: There is low institutional interest in the stock, suggesting limited buying pressure.

Correlation Analysis: The stock has a high beta relative to the market, indicating a strong inverse correlation.

Relative Valuation: The stock is trading at the lower end of its historical range, making it relatively cheap.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $15.34 (resistance)
  • SMA 50: $16.51 (resistance)

Breakout/Breakdown Levels:

  • Upper Bollinger Band: $17.43 (resistance)

Time-Sensitive Catalysts: There are no near-term catalysts that could significantly impact the stock's price.

Risk Management: Stop-loss levels should be set at the SMA 20 and SMA 50 levels to limit potential losses. Position sizing considerations should prioritize caution due to high volatility.

Generated
Earnings History
20 of 21 under expected move
Avg Expected Move
23.30%
Avg Actual Move
3.93%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-24 Pre-Market 15.50% 2.87% 0.19x Within
2021-05-05 Pre-Market 16.35% 2.26% 0.14x Within
2021-08-04 Pre-Market 46.69% 3.84% 0.08x Within
2021-11-03 Pre-Market 14.62% 1.45% 0.10x Within
2022-11-03 Pre-Market 19.11% 0.89% 0.05x Within
2023-02-14 Pre-Market 23.59% 0.12% 0.01x Within
2023-05-03 Pre-Market 18.83% 6.99% 0.37x Within
2023-08-02 Pre-Market 15.88% 3.52% 0.22x Within
2023-11-09 Pre-Market 18.40% 4.88% 0.27x Within
2024-02-14 Pre-Market 37.29% 8.84% 0.24x Within
2024-04-05 Pre-Market 20.15% 5.49% 0.27x Within
2024-08-01 Pre-Market 54.40% 2.20% 0.04x Within
2024-11-07 After-Close 17.76% 3.37% 0.19x Within
2025-02-11 Pre-Market 33.85% 1.56% 0.05x Within
2025-05-01 Pre-Market 13.93% 0.00% 0.00x Within
2025-08-05 After-Close 23.53% 5.79% 0.25x Within
2025-11-05 Pre-Market 24.82% 3.96% 0.16x Within
2026-01-12 Pre-Market 12.53% 15.86% 1.27x Exceeded
2026-05-05 Pre-Market 22.59% 4.97% 0.22x Within
2026-07-29 Pre-Market 20.43% 0.18% 0.01x Within
2026-11-04 Pre-Market 19.09% 3.53% 0.18x Within

Earnings calendar: this week’s reports with expected vs actual moves →

ADPT Options Activity & IV Rank

ADPT IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 96.1%
7-DTE IV: 99.0%
Expected Move: $7.52
7-DTE Move: $3.70
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 301
Put Volume: 232
P/C Volume: 0.771
NEUTRAL
Call OI: 4,632
Put OI: 1,827
P/C OI: 0.394
Total OI: 6,459

ATM Options Pricing

ATM Call: $4.10
ATM Put: $3.42
Call %: 13.5%
Put %: 11.3%

Chain Summary

Chain Volume: 533
Chain OI: 6,459
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 100th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
100%
vs own history
GEX tilt
+1.00
OI-weighted, today
Vanna tilt
+0.59
δ-sensitivity to IV
Charm tilt
-0.04
δ-decay vs time
Vanna tilt +0.59: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 6 ATM contracts, 3k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)22.9LowNov 9
IV Rank (30 DTE)72.2MediumNov 9

Embed ADPT IV rank

ADPT's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$7.52Nov 9
Beta Analysis

Risk Metrics

Beta: 1.5285
Alpha: 74.87%
Correlation: 0.3152
R-Squared: 9.9%
Stock Volatility: 66.7%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ADPT
6 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Viking Global Hedge fund
Andreas Halvorsen
$643.4M
1.83%
#21 of 900.0%13F
Millennium Management Hedge fund
Izzy Englander
$10.8M
0.01%
#1521 of 3716-53.3%13F
Renaissance Technologies Hedge fund
Jim Simons
$6.5M
0.01%
#1304 of 3138+26.3%13F
Citadel Hedge fund
Ken Griffin
$3.9M
0.00%
#2294 of 6285-50.1%13F
Bridgewater Associates Hedge fund
Ray Dalio
$860K
0.00%
#857 of 997-55.3%13F
Rockefeller Capital Management Family office
Rockefeller family
$368K
0.00%
#2249 of 4729-0.6%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ADPT Institutional Ownership (13F)

Filings for 2026-06-30 · 117 already for 2026-09-30
Diluted shares outstanding: 157,565,087 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

311 filers164,344,671 shares$3.53B value104.30% of float
# Filer Shares Value % of Total % of Float Period
1 VIKING GLOBAL INVESTORS LP 29,993,708 $643.37M 18.22% 19.04% 2026-06-30
2 BlackRock, Inc. Custodian 15,139,159 $324.73M 9.20% 9.61% 2026-06-30
3 Vanguard Capital Management LLC 6,403,587 $137.36M 3.89% 4.06% 2026-06-30
4 Wellington Management Group LLP Custodian 5,911,366 $126.80M 3.59% 3.75% 2026-06-30
5 Vanguard Portfolio Management LLC 5,476,231 $117.47M 3.33% 3.48% 2026-06-30
6 Geode Capital Management, LLC Custodian 3,720,520 $107.54M 3.05% 2.36% 2026-09-30
7 D. E. Shaw & Co., Inc. Custodian 4,625,859 $99.22M 2.81% 2.94% 2026-06-30
8 WESTFIELD CAPITAL MANAGEMENT CO LP 4,267,645 $91.54M 2.59% 2.71% 2026-06-30
9 State Street Corp 3,458,388 $74.18M 2.10% 2.19% 2026-06-30
10 Principal Financial Group, Inc. 2,445,689 $70.68M 2.00% 1.55% 2026-09-30
11 Invesco Ltd. Custodian 3,094,011 $66.37M 1.88% 1.96% 2026-06-30
12 Goldman Sachs Group Inc Custodian 2,984,227 $64.01M 1.81% 1.89% 2026-06-30
13 T. Rowe Price Associates, Inc. 2,665,308 $57.17M 1.62% 1.69% 2026-06-30
14 Driehaus Capital Management LLC 2,527,703 $54.22M 1.54% 1.60% 2026-06-30
15 Arrowstreet Capital, Limited Partnership 2,524,620 $54.15M 1.53% 1.60% 2026-06-30
16 LORD, ABBETT & CO. LLC 2,474,814 $53.09M 1.50% 1.57% 2026-06-30
17 Nuveen, LLC Custodian 2,366,155 $50.75M 1.44% 1.50% 2026-06-30
18 BNP PARIBAS ASSET MANAGEMENT Holding S.A. 2,182,326 $46.81M 1.33% 1.39% 2026-06-30
19 FRED ALGER MANAGEMENT, LLC 2,092,284 $44.88M 1.27% 1.33% 2026-06-30
20 ARK Investment Management LLC 2,090,306 $44.84M 1.27% 1.33% 2026-06-30
21 NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 1,889,188 $40.52M 1.15% 1.20% 2026-06-30
22 Aristotle Atlantic Partners, LLC 1,838,513 $39.44M 1.12% 1.17% 2026-06-30
23 T. Rowe Price Investment Management, Inc. 1,779,651 $38.17M 1.08% 1.13% 2026-06-30
24 Bank of America Corp Custodian 1,730,044 $37.11M 1.05% 1.10% 2026-06-30
25 Jane Street Group, LLC Custodian 1,590,513 $34.12M 0.97% 1.01% 2026-06-30
8 filers$146.28M notional
# Filer Notional Value % of Total Period
1 UBS Group AG Custodian $61.39M 41.97% 2026-06-30
2 Susquehanna International Group, LLP Custodian $42.28M 28.91% 2026-06-30
3 TORONTO DOMINION BANK $38.61M 26.39% 2026-06-30
4 Citadel Advisors LLC Custodian $1.65M 1.13% 2026-06-30
5 Jane Street Group, LLC Custodian $1.16M 0.79% 2026-06-30
6 Simplex Trading, LLC Custodian $910.35K 0.62% 2026-09-30
7 Belvedere Trading LLC $262.99K 0.18% 2026-09-30
8 GROUP ONE TRADING LLC Custodian $4.29K <0.01% 2026-06-30
2 filers$807.96K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $669.24K 82.83% 2026-06-30
2 Simplex Trading, LLC Custodian $138.72K 17.17% 2026-09-30

ADPT Insider Trading (Form 4)

Latest: 2026-11-06
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-06 Julie Rubinstein President and COO Mixed
Sell −35,643 · Exer +35,643
 — $19.46 -$521.7K EDGAR
2026-11-03 Julie Rubinstein President and COO Mixed
Exer +35,643 · Sell −35,643
 — $19.10 -$496.2K EDGAR
2026-10-29 Julie Rubinstein President and COO Mixed
Sell −35,643 · Exer +35,643
 — $20.07 -$565.4K EDGAR
2026-10-26 Julie Rubinstein President and COO Mixed
Sell −35,643 · Exer +35,643
 — $18.66 -$464.8K EDGAR
2026-10-21 Julie Rubinstein President and COO Mixed
Exer +35,643 · Sell −35,643
 — $18.40 -$446.4K EDGAR
2026-10-16 Julie Rubinstein President and COO Mixed
Exer +35,643 · Sell −35,643
 — $18.66 -$464.6K EDGAR
2026-10-13 Julie Rubinstein President and COO Mixed
Exer +35,643 · Sell −35,643
 — $18.97 -$487.2K EDGAR
2026-10-08 Susan Bobulsky Chief Commercial Officer, MRD Sell (S) −6,444 $30.00 -$193.3K EDGAR
2026-10-08 Julie Rubinstein President and COO Mixed
Sell −35,643 · Exer +35,643
 — $19.37 -$515.5K EDGAR
2026-10-05 Julie Rubinstein President and COO Mixed
Exer +35,643 · Sell −35,643
 — $20.30 -$581.6K EDGAR
2026-10-05 Francis Lo Chief People Officer Mixed
Exer +26,792 · Sell −26,792
 — $17.53 -$576.1K EDGAR
2026-09-18 Francis Lo Chief People Officer Mixed
Exer +105,560 · Sell −115,406
 −9,846 $19.23 -$2.23M EDGAR
2026-09-17 Susan Bobulsky Chief Commercial Officer, MRD Sell (S) −1,195 $27.00 -$32.3K EDGAR
2026-09-02 Katey Einterz Owen Director Gift (G) −12,539 — EDGAR
2026-08-28 Katey Einterz Owen Director Sell (S) −9,615 $26.00 -$250.0K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ADPT Insider Holdings

12 insiders · @ $30.26
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Chad M Robins CEO and Chairman 2,683,043 $81.19M -$88.62M 43 2026-08-19
2 Harlan S Robins Chief Scientific Officer 1,312,058 $39.70M -$70.21M 50 2026-07-23
3 Susan Bobulsky Chief Commercial Officer, MRD 389,350 $11.78M -$3.50M 18 2026-10-08
4 Julie Rubinstein President and COO 377,802 $11.43M -$89.12M 65 2026-11-06
5 Sharon Benzeno Chief Commercial Ofc Imm Med 272,751 $8.25M -$26.24M 35 2026-03-13
6 Kyle Piskel Chief Financial Officer 256,725 $7.77M -$3.76M 20 2026-05-20
7 Peter M Neupert Director 255,315 $7.73M -$3.21M 11 2026-08-19
8 Francis Lo Chief People Officer 242,065 $7.32M -$16.76M 34 2026-10-05
9 Robert Hershberg Director 77,347 $2.34M -$3.42M 23 2026-08-20
10 Michael J Pellini Director 69,690 $2.11M -$6.43M 10 2025-03-06
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ADPT Board & Officers

As of SEC filings through Nov 6, 2026

Directors 5

Officers 7

Changes in the last 10 years (65)
Mar 6, 2025Julie Rubinstein listed as President and COO (previously President) in SEC filings
May 17, 2024Kyle Piskel listed as Chief Financial Officer (previously Principal Accounting Officer) in SEC filings
Apr 1, 2024The company announced the departure of Tycho Peterson as Chief Financial Officer in an SEC filing
Mar 6, 2024Susan Bobulsky listed as Chief Commercial Officer, MRD (previously SVP, Diagnostics, clonoSEQ) in SEC filings
Sep 1, 2023The company announced the departure of Kevin T Conroy from the board in an SEC filing
Jul 28, 2023The company announced the departure of Nitin Sood as Chief Commercial Officer, MRD in an SEC filing
Jun 9, 2023The company announced the departure of Leslie Trigg from the board in an SEC filing
Apr 7, 2023The company announced the departure of R Mark Adams as Chief Operating Officer in an SEC filing
Mar 8, 2023Sharon Benzeno listed as Chief Commercial Ofc Imm Med (previously Chief Business Development Off) in SEC filings
Aug 5, 2022Nitin Sood listed as Chief Commercial Officer, MRD (previously Chief Commercial Officer) in SEC filings
Jun 1, 2022Tycho Peterson became Chief Financial Officer
Jan 4, 2022The company announced the departure of Chad M Cohen as Chief Financial Officer in an SEC filing
Nov 3, 2021Kyle Piskel listed as Principal Accounting Officer (previously Corporate Controller) in SEC filings
Aug 4, 2021Nitin Sood became Chief Commercial Officer
Apr 21, 2021Jyoti Palaniappan listed as SVP, Diagnostics, T-Detect (previously SVP, Diagnostics, immunoSEQ Dx) in SEC filings
Apr 9, 2021R Mark Adams listed as Chief Operating Officer (previously Chief Technical Officer) in SEC filings
Mar 29, 2021Henning Thorsen became SVP, Commercial Operations
Mar 17, 2021Leslie Trigg became a director
Mar 17, 2021Katey Einterz Owen became a director
Sep 16, 2020Charles Sang listed as SVP, External Affairs (previously SVP, Clinical Diagnostics) in SEC filings
Not reported recently (26)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

ADPT Proposed Insider Sales (Form 144)

Latest: 2026-10-06
Last 30d: 0 filings  ·  Last 90d: 14 filings · $63.6M notice value · 8 unique filers · 36% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Harlan Robins (4, $29.6M) · Chad Robins (2, $14.8M) · JULIE RUBINSTEIN (1, $11.0M) · FRANCIS LO (1, $3.8M) · PETER NEUPERT (1, $3.1M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-06 SUSAN BOBULSKY Officer 6,444 $192.3K 2026-10-06 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-10-01 JULIE RUBINSTEIN Officer 379,777 $10.98M 2026-10-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-16 FRANCIS LO Officer 142,198 $3.79M 2026-09-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-15 SUSAN BOBULSKY Officer 1,195 $29.6K 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-26 KATHERINE E OWEN Director 9,615 $250.0K 2026-08-26 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-20 Harlan Robins Former Officer 402,160 $10.23M 2026-08-20 Goldman Sachs & Co. LLC — EDGAR
2026-08-19 Harlan Robins Former Officer 215,632 $5.50M 2026-08-19 Goldman Sachs & Co. LLC — EDGAR
2026-08-18 Chad Robins Officer 278,676 $6.84M 2026-08-18 Goldman Sachs & Co. LLC — EDGAR
2026-08-18 Harlan Robins Former Officer 261,044 $6.41M 2026-08-18 Goldman Sachs & Co. LLC — EDGAR
2026-08-18 ROBERT M HERSHBERG Director 30,664 $748.3K 2026-08-18 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-04 Earnings results EDGAR
2026-07-29 Earnings results · Director or officer change EDGAR
2026-06-22 Material agreement · Agreement terminated · New debt obligation · Unregistered share sale · Other events EDGAR
2026-06-15 Other events EDGAR
2026-06-09 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-04 0001193125-26-447411 EDGAR
2026-08-04 0001193125-26-332940 EDGAR
ETF Holders
72 ETFs hold ADPT
25 shown · $589.19M total exposure · 0.12% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.01% $140.5M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.15% $115.8M $76.6B 2026-11-06
3 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.03% $49.3M — 2026-09-30
4 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.31% $42.1M $13.7B 2026-11-06
5 VXF Vanguard Extended Market ETF Vanguard 0.04% $41.1M — 2026-09-30
6 IBB iShares Biotechnology ETF iShares (BlackRock) 0.30% $32.8M $11.1B 2026-11-06
7 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.48% $31.5M $6.6B 2026-11-05
8 VBK Vanguard Morningstar Small-Cap Growth ETF Vanguard 0.06% $27.5M — 2026-09-30
9 VTWO Vanguard Russell 2000 ETF Vanguard 0.15% $26.7M — 2026-09-30
10 SCHA Schwab U.S. Small-Cap ETF Nport 0.06% $14.6M — 2026-08-31
11 VHT Vanguard Health Care ETF Vanguard 0.05% $10.6M — 2026-09-30
12 FYC First Trust Small Cap Growth AlphaDEX® Fund First Trust 0.64% $8.3M $1.3B 2026-11-06
13 FTXH First Trust Nasdaq Pharmaceuticals ETF First Trust 0.53% $6.3M $1.2B 2026-11-06
14 SMLF iShares U.S. Small-Cap Equity Factor ETF iShares (BlackRock) 0.13% $5.3M $4.2B 2026-11-06
15 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.30% $5.0M — 2026-09-30
16 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.01% $4.8M $93.2B 2026-11-06
17 PSC Principal U.S. Small-Cap ETF Nport 0.18% $4.2M — 2026-06-30
18 FYX First Trust Small Cap Core AlphaDEX® Fund First Trust 0.30% $4.1M $1.4B 2026-11-06
19 BRES Burney U.S. Equity Select ETF Nport 0.57% $3.8M — 2026-07-31
20 DWAS Invesco Dorsey Wright SmallCap Momentum ETF Nport 0.82% $3.4M — 2026-08-31
21 BRNY Burney U.S. Factor Rotation ETF Nport 0.57% $3.3M — 2026-07-31
22 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.08% $2.3M — 2026-07-31
23 RSSL Global X Russell 2000 ETF Global X 0.15% $2.1M — 2026-11-06
24 ESML iShares ESG Aware MSCI USA Small-Cap ETF iShares (BlackRock) 0.07% $1.9M $2.7B 2026-11-06
25 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $1.9M — 2026-08-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.41
TTM Revenue
$308.08M
TTM Net Income
$-63.85M
TTM Op. Cash Flow
$-21.01M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$71.55M$-39.79M$-0.25$-6.40M
Q1 '262026-03-31$70.87M$-20.03M$-0.13$-9.54M
Q4 '252025-12-31$71.68M$-13.58M$-0.09$2.06M
Q3 '252025-09-30$93.97M$9.55M$0.06$-7.13M
Q2 '252025-06-30$58.88M$-25.61M$-0.17$-12.43M
Q1 '252025-03-31$52.44M$-29.85M$-0.20$-28.48M
Q4 '242024-12-31$47.46M$-33.69M$-0.22$-12.49M
Q3 '242024-09-30$46.44M$-32.07M$-0.22$-27.07M
Q2 '242024-06-30$43.19M$-46.22M$-0.31$-17.30M
Q1 '242024-03-31$41.87M$-47.51M$-0.33$-38.35M
Q4 '232023-12-31$45.78M$-69.44M$-0.48$-26.93M
Q3 '232023-09-30$37.92M$-50.30M$-0.35$-46.68M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-04
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
31.65
P/S
15.48
EV/EBITDA
—
EV/Sales
16.01
ROE
-42.4%
ROA
-10.0%
Div Yield
0.00%
FCF Yield
-0.44%
Debt/Equity
2.22
Current Ratio
—
Market Cap
$4.77B
as of 2026-11-09

ADPT vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 45.8 +45.5% +30.7% 27
VRTX Vertex Pharmaceuticals Inc $138.7B 35.4 +10.5% +21.8% 64
MRNA Moderna, Inc. Common Stock $101.5B — −27.6% +771.7% 53
NTRA Natera, Inc. Common Stock $45.1B — +36.6% +40.0% 43
GH Guardant Health, Inc. Common Stock $20.4B — +42.7% +56.1% 23
TWST Twist Bioscience Corporation Common Stoc $8.0B — +17.8% +317.8% 92
CRSP CRISPR Therapeutics AG $4.9B — −34.3% −6.9% 37
ADPT Adaptive Biotechnologies Corporation Com $4.5B — +50.1% +90.2% 72
CDNA CareDx, Inc. $4.1B 35.3 +38.9% +341.1% 37
Peer median $32.7B 35.4 +27.2% +48.0% 40

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
11.99M
SI % of Float
9.95%
Days to Cover
5.03
Short Vol Ratio
52.6%
Free Float
120.51M
Float %
75.5%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24